Forxiga approved in China to reduce the risk of cardiovascular death and hospitalisation in adult patients with symptomatic chronic heart failure
Forxiga approved in China to reduce the risk of cardiovascular death and hospitalisation in adult patients with symptomatic chronic heart failureThe first and only heart failure therapy with a proven mortality benefit now approved for patients with heart failure regardless of ejection fraction status Forxiga&nb...